THE ARISING MAGAZINES
This subject now has a monthly magazine.
Read the current magazine and connected articles →
The earlier guide and its original links remain below.
Magazine
Reading the evidence
Biological-age tests, fish oil and fasting show why the measured outcome matters. Three full articles trace the distance between an interesting signal and a demonstrated benefit.
25 OCTOBER 2026 · VERSION 1.1 · 3 FULL ARTICLES
Read the articles online
- When your biological-age number moves, what moved?Repeating a laboratory result is not the same as measuring a stable trait
- Fish oil reached the brain. The hoped-for benefit did not follow.A two-year DHA trial separates biological activity from clinical benefit
- Fasting and muscle: the unanswered part of the weight-loss storySmall short-term differences in lean mass do not settle long-term function
26 OCTOBER 2026 · ONLINE UPDATE
Nicotinamide riboside did not improve early Parkinson’s outcomes
The NOPARK article in The Arising’s October 25 edition reports a randomized, double-blind trial of 410 people with early Parkinson’s disease. Nicotinamide riboside, 500 mg twice daily for 52 weeks, did not improve clinical outcomes compared with placebo; 393 participants were included in the primary analysis.
The primary symptom-score difference was 2.72 points in favor of placebo (95% confidence interval, 0.47–4.98), below the trial’s stated 5.2-point threshold for clinically important worsening. This result concerns one compound, dose, disease and duration. It does not establish a benefit for healthy aging or settle every question about NAD biology.
Serious adverse events occurred in 17 of 205 participants receiving nicotinamide riboside and 29 of 205 receiving placebo in the safety analysis. These counts alone do not establish that the supplement is safer.
Primary study · published October 8, 2026 ↗ · Trial registry ↗
This online update connects Monday’s discussion to the collection. It is additional reading, not part of the October 25 PDF’s three articles. Review depth: primary abstract and selected registry fields; the full paper, supplements and complete funding and conflict disclosures have not been appraised here.
Where this leads next
THE CONNECTED READING COLLECTION
Forty-eight subjects.
A wider conversation.
The expanded physician-review collection connects each booklet to related reading and the Atlas. Access follows the shared Atlas settings.
Open the shared booklet collection →A worked example
CoQ10 and physical capacity: why a mechanism, a pooled estimate and a useful change in daily life are different questions.
Does it help patients?
A November 2 Arising discussion uses cerebral embolic protection during valve replacement as a worked example of the difference between a plausible mechanism and patient-outcome evidence. The research appeared online in May 2026. The linked dispatch preserves the uncertainties and review limits. This reading connection does not revise the dated booklet PDF.
Benefit and tolerability
Read the mazdutide trial in context →
A connection for further reading, not evidence of a strength or lifespan benefit.
November 4, 2026 · Online field note
Recovery after stroke
After a stroke, the question that matters at home is what a person can do independently. The ATTENTION LATE trial used that question to judge an extra treatment for a blocked basilar artery, which supplies the brainstem.
At 40 hospitals in China, 330 adults who arrived directly at a thrombectomy center 4½ to 24 hours after stroke onset were randomly assigned to clot removal alone or the same procedure preceded by tenecteplase, a clot-dissolving drug. At three months, 50 people in each group could manage their daily affairs independently: about 30% either way.
The extra drug did not improve measured independence in this late-window group. That gives stroke teams an answer for a particular artery, arrival time and treatment setting. It also illustrates a useful way to read any trial: look for the outcome someone would notice back at the kitchen table.
Read the randomized trial in JAMA · Trial registration · Public Atlas · The Arising